Patient Safety and Efficacy Evaluations
PD, Tumor
ADVERSE EVENT, ADVERSE EVENT, TUMOR
Adverse events (AEs) were documented using Common Terminology Criteria for Adverse Events, version 4. Alisertib dose levels/modifications are provided in eTable 1 in Within 14 days of registration, before each cycle, and at PD, patients underwent toxic effect assessments. Tumor assessments were performed after every 2 cycles.